Issue link: https://www.e-digitaleditions.com/i/922724
Tablets & Capsules January 2018 7 Kao at the University of Alberta. Her team randomly assigned 116 adults diagnosed with RCDI to receive either a single FMT capsule or colonoscopy treatment. After 12 weeks, about 96.2 percent of patients in the capsule group and the colonoscopy group didn't have RCDI. The less invasive FMT capsule treatment was rated as "not at all unpleasant" by 66 percent of the patients in the capsule group. An article about the study appeared in the November 28, 2017, issue of JAMA. new editorial advisor We're pleased to announce that M u r a l i k r i s h n a n "Kris" Angamuthu has joined T&C's Editorial Advisory Board. Angamuthu is an investigator for drug product development, specialty dosage forms, at GlaxoSmithKline in Collegeville, PA. His work there has involved developing a unique dosage form for treating nicotine addiction and smoking cessation, which is in clinical trials in the USA. He has also worked at Amgen, Novartis Consumer Healthcare, and German Remedies. He co-wrote the article "Assessing the performance of a co-processed HPMC-lactose excipient using an instrumented tablet press," which appeared in T&C's September 2015 issue. His research has been reported in several peer-reviewed journals and scientific posters. He has also written two book chapters. research news Oral capsule as effective as colonic delivery in treating RCDI EDMONTON, AB, Canada— Fecal microbiota transplantation (FMT) via oral capsule is as effective as FMT via colonoscopy at treating recurrent Clostridium difficile infec- tion (RCDI), according to Dr. Dina markets Pharmaceutical continuous manufacturing technology to grow 8.8 percent annually ALBANY, NY— The benefits of pharmaceutical continuous manufac- turing—including reduced fluctua- tions in production, improved yields, and lower costs of operation and equipment—will drive the market for the technology it employs to grow at an annual rate of 8.8 percent through 2025, according to a report from Transparency Market Research. The report cites FDA initiatives encourag- ing manufacturers to switch to con- tinuous manufacturing as drivers of growth in North America. The global market, valued at $1.74 billion in 2016, is forecast to reach $3.7 bil- lion by 2025. HEALTH FROM A DIFFERENT ANGLE CAPSULES ARE THE VERY ESSENCE OF QUALICAPS ® As a company dedicated to capsules we have a unique perspective on how to contribute to health. Qualicaps ® delivers pharmaceutical-grade capsules together with a comprehensive service along the drug product life cycle through our global team of commercial, scientific and technical experts. www.qualicaps.com